Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders

Abstract

The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 12 / 724,829, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61 / 160,642, filed Mar. 16, 2009; U.S. Provisional Patent Application Ser. No. 61 / 177,958, filed May 13, 2009; and U.S. Provisional Patent Application Ser. No. 61 / 227,620 filed Jul. 22, 2009. Each of the above-referenced applications is hereby incorporated herein by reference in its entirety.BACKGROUND[0002]Oxidative stress and inflammation are implicated in the pathogenesis of metabolic diseases, diabetes, obesity, dyslipidemia and their associated cardiovascular complications. For example, oxidative stress is a common pathogenic factor leading to insulin resistance,β-cell dysfunction, impaired glucose tolerance, and type 2 diabetes mellitus. With regard to inflammation, clinical studies suggest that acute hyperglycemia results in elevated levels of circulating inflammatory cytokines s...

AI Technical Summary

Benefits of technology

[0011]The compounds of the present invention, in particular Example 1 (salnacedin) and Example 13 (conjugate comprised of diflunisal and NAC), show additive or synergistic effects relative to treatment with an antioxidant agent alone or an anti-inflammatory agent alone. The additive or synergistic effect improves the anti-diabetic effect while reducing side effects associated with monotherapy. In particular, treatment with Example 1 or Example 13 improves anti-diabetic effects while lowering the risk of gastric bleeding, associated with salicylic acid, and / or tinnitus, associated with N-acetylcysteine.

[0012]The present invention provides compounds of Formula (I)-(XXII) as defined herein. In another aspect, the present invention provides pharmaceutical compositions comprised of a compound of Formula (I)-(XXII) and at least one pharmaceutically acceptable carrier. The compounds of Formula (I)-(XXII) and the pharmaceutical compositions comprised of Formula (I)-(IX) and at least one pharmaceutically acceptable carrier are useful for treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, Chronic Obstructive Pulmonary Disease (COPD), cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, Latent Autoimmune Diabetes of Adulthood (LADA), metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance. The compounds and pharmaceutical compositions of the present invention are useful for protecting pancreatic β-cells, preventing their impairment or failure and subsequent lower insulin secretion. Also, the compounds and pharmaceutical compositions of the present invention are also useful for reducing free fatty acids (FFA), triglycerides, advanced glycated end products (AGEs), ROS, lipid peroxidation, tissue and plasma TNFα and IL6 levels, or for delaying or preventing cardiovascular complications associated with atherosclerosis.

[0014]In another aspect, the present invention provides uses for compounds of Formula (I)-(XXII), or pharmaceutical compositions comprised of a compound of Formula (I)-(XXII) and at least one pharmaceutically acceptable carrier, for preparing, or for the manufacture of, a medicament for treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, Chronic Obstructive Pulmonary Disease (COPD), cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, Latent Autoimmune Diabetes of Adulthood (LADA), metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance in a mammal or human patient. The present invention also provides uses for compounds of Formula (I)-(XXII) or pharmaceutical compositions comprised of a compound of Formula (I)-(XXII) and at least one pharmaceutically acceptable carrier, for preparing, or for the manufacture of, a medicament for reducing free fatty acids (FFA), triglycerides, advanced glycated end products (AGEs), ROS, lipid peroxidation, tissue and plasma TNFα and IL6 levels, or for delaying or preventing cardiovascular complications associated with atherosclerosis in a mammal or human patient. The present invention also provides uses for compounds of Formula (I)-(XXII), or pharmaceutical compositions comprised of a compound of Formula (I)-(XXII) and at least one pharmaceutically acceptable carrier, for preparing, or for the manufacture of, a medicament for protecting pancreatic β-cells, preventing their impairment or failure and subsequent lower insulin secretion, in a mammal or human patient.

Problems solved by technology

However, while cells have a number of available anti-oxidant mechanisms, damage most likely occurs when the ROS is excessive and / or anti-oxidant pathways are overwhelmed as is frequently the case in diabetes.

The consequence of limited scavenging systems is that ROS concentration in β-cells may increase rapidly, damaging the β-cells.

Also, high doses of salicylic acid lower blood glucose levels.

However, at this high dose, side effects, such as tinnitus, are enhanced by 66% and the long term risk of gastric bleeding and ulceration is also increased.

Images